(UHS) Universal Health - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US9139031002
Stock:
Total Rating 47
Risk 84
Buy Signal -0.50
| Risk 5d forecast | |
|---|---|
| Volatility | 41.9% |
| Relative Tail Risk | -9.78% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.36 |
| Alpha | 2.77 |
| Character TTM | |
|---|---|
| Beta | 0.635 |
| Beta Downside | 0.718 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.64% |
| CAGR/Max DD | 0.51 |
EPS (Earnings per Share)
Revenue
Description: UHS Universal Health
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. It operates through Acute Care Hospital Services and Behavioral Health Care Services segments. The company's hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric, pharmacy, and/or behavioral health services. It also provides commercial health insurance services; and various management services, including central purchasing, information services, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. The company was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 1.38b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.48 > 1.0 |
| NWC/Revenue: 0.58% < 20% (prev 5.13%; Δ -4.55% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.95b > Net Income 1.38b |
| Net Debt (5.00b) to EBITDA (2.58b): 1.94 < 3 |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.0m) vs 12m ago -4.58% < -2% |
| Gross Margin: 90.34% > 18% (prev 0.90%; Δ 8944 % > 0.5%) |
| Asset Turnover: 114.4% > 50% (prev 107.4%; Δ 7.02% > 0%) |
| Interest Coverage Ratio: 12.90 > 6 (EBITDA TTM 2.58b / Interest Expense TTM 153.5m) |
Altman Z'' 4.57
| A: 0.01 (Total Current Assets 3.26b - Total Current Liabilities 3.16b) / Total Assets 15.34b |
| B: 0.51 (Retained Earnings 7.87b / Total Assets 15.34b) |
| C: 0.13 (EBIT TTM 1.98b / Avg Total Assets 14.85b) |
| D: 1.87 (Book Value of Equity 15.04b / Total Liabilities 8.05b) |
| Altman-Z'' Score: 4.57 = AA |
Beneish M -2.98
| DSRI: 1.06 (Receivables 2.59b/2.21b, Revenue 16.99b/15.42b) |
| GMI: 0.99 (GM 90.34% / 89.78%) |
| AQI: 0.94 (AQ_t 0.31 / AQ_t-1 0.33) |
| SGI: 1.10 (Revenue 16.99b / 15.42b) |
| TATA: -0.04 (NI 1.38b - CFO 1.95b) / TA 15.34b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of UHS shares?
As of March 01, 2026, the stock is trading at USD 206.10 with a total of 1,367,827 shares traded.
Over the past week, the price has changed by -10.58%, over one month by +1.71%, over three months by -15.34% and over the past year by +11.23%.
Over the past week, the price has changed by -10.58%, over one month by +1.71%, over three months by -15.34% and over the past year by +11.23%.
Is UHS a buy, sell or hold?
Universal Health has received a consensus analysts rating of 3.79.
Therefor, it is recommend to hold UHS.
- StrongBuy: 7
- Buy: 1
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UHS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 251.2 | 21.9% |
| Analysts Target Price | 251.2 | 21.9% |
UHS Fundamental Data Overview February 24, 2026
P/E Trailing = 11.0762
P/E Forward = 9.2081
P/S = 0.8711
P/B = 2.0087
P/EG = 1.87
Revenue TTM = 16.99b USD
EBIT TTM = 1.98b USD
EBITDA TTM = 2.58b USD
Long Term Debt = 3.95b USD (from longTermDebt, last quarter)
Short Term Debt = 813.5m USD (from shortTermDebt, last quarter)
Debt = 5.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.00b USD (from netDebt column, last quarter)
Enterprise Value = 19.80b USD (14.80b + Debt 5.11b - CCE 112.9m)
Interest Coverage Ratio = 12.90 (Ebit TTM 1.98b / Interest Expense TTM 153.5m)
EV/FCF = 20.85x (Enterprise Value 19.80b / FCF TTM 949.6m)
FCF Yield = 4.80% (FCF TTM 949.6m / Enterprise Value 19.80b)
FCF Margin = 5.59% (FCF TTM 949.6m / Revenue TTM 16.99b)
Net Margin = 8.09% (Net Income TTM 1.38b / Revenue TTM 16.99b)
Gross Margin = 90.34% ((Revenue TTM 16.99b - Cost of Revenue TTM 1.64b) / Revenue TTM)
Gross Margin QoQ = 90.78% (prev 90.22%)
Tobins Q-Ratio = 1.29 (Enterprise Value 19.80b / Total Assets 15.34b)
Interest Expense / Debt = 0.75% (Interest Expense 38.4m / Debt 5.11b)
Taxrate = 23.70% (117.8m / 496.9m)
NOPAT = 1.51b (EBIT 1.98b * (1 - 23.70%))
Current Ratio = 1.03 (Total Current Assets 3.26b / Total Current Liabilities 3.16b)
Debt / Equity = 0.71 (Debt 5.11b / totalStockholderEquity, last quarter 7.23b)
Debt / EBITDA = 1.94 (Net Debt 5.00b / EBITDA 2.58b)
Debt / FCF = 5.26 (Net Debt 5.00b / FCF TTM 949.6m)
Total Stockholder Equity = 6.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.26% (Net Income 1.38b / Total Assets 15.34b)
RoE = 19.85% (Net Income TTM 1.38b / Total Stockholder Equity 6.93b)
RoCE = 18.20% (EBIT 1.98b / Capital Employed (Equity 6.93b + L.T.Debt 3.95b))
RoIC = 13.11% (NOPAT 1.51b / Invested Capital 11.52b)
WACC = 6.28% (E(14.80b)/V(19.91b) * Re(8.25%) + D(5.11b)/V(19.91b) * Rd(0.75%) * (1-Tc(0.24)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.63%
[DCF] Terminal Value 87.08% ; FCFF base≈952.5m ; Y1≈1.17b ; Y5≈2.00b
[DCF] Fair Price = 843.6 (EV 51.59b - Net Debt 5.00b = Equity 46.59b / Shares 55.2m; r=6.28% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 11.74 | EPS CAGR: -42.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.55 | Revenue CAGR: 8.81% | SUE: 3.02 | # QB: 2
EPS next Quarter (2026-03-31): EPS=5.29 | Chg7d=+0.000 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=10
EPS next Year (2026-12-31): EPS=23.39 | Chg7d=+0.000 | Chg30d=-0.072 | Revisions Net=-3 | Growth EPS=+7.4% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -0.8% (Discount Rate 8.2% - Earnings Yield 9.0%)
[Growth] Growth Spread = +6.5% (Analyst 5.7% - Implied -0.8%)
P/E Forward = 9.2081
P/S = 0.8711
P/B = 2.0087
P/EG = 1.87
Revenue TTM = 16.99b USD
EBIT TTM = 1.98b USD
EBITDA TTM = 2.58b USD
Long Term Debt = 3.95b USD (from longTermDebt, last quarter)
Short Term Debt = 813.5m USD (from shortTermDebt, last quarter)
Debt = 5.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.00b USD (from netDebt column, last quarter)
Enterprise Value = 19.80b USD (14.80b + Debt 5.11b - CCE 112.9m)
Interest Coverage Ratio = 12.90 (Ebit TTM 1.98b / Interest Expense TTM 153.5m)
EV/FCF = 20.85x (Enterprise Value 19.80b / FCF TTM 949.6m)
FCF Yield = 4.80% (FCF TTM 949.6m / Enterprise Value 19.80b)
FCF Margin = 5.59% (FCF TTM 949.6m / Revenue TTM 16.99b)
Net Margin = 8.09% (Net Income TTM 1.38b / Revenue TTM 16.99b)
Gross Margin = 90.34% ((Revenue TTM 16.99b - Cost of Revenue TTM 1.64b) / Revenue TTM)
Gross Margin QoQ = 90.78% (prev 90.22%)
Tobins Q-Ratio = 1.29 (Enterprise Value 19.80b / Total Assets 15.34b)
Interest Expense / Debt = 0.75% (Interest Expense 38.4m / Debt 5.11b)
Taxrate = 23.70% (117.8m / 496.9m)
NOPAT = 1.51b (EBIT 1.98b * (1 - 23.70%))
Current Ratio = 1.03 (Total Current Assets 3.26b / Total Current Liabilities 3.16b)
Debt / Equity = 0.71 (Debt 5.11b / totalStockholderEquity, last quarter 7.23b)
Debt / EBITDA = 1.94 (Net Debt 5.00b / EBITDA 2.58b)
Debt / FCF = 5.26 (Net Debt 5.00b / FCF TTM 949.6m)
Total Stockholder Equity = 6.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.26% (Net Income 1.38b / Total Assets 15.34b)
RoE = 19.85% (Net Income TTM 1.38b / Total Stockholder Equity 6.93b)
RoCE = 18.20% (EBIT 1.98b / Capital Employed (Equity 6.93b + L.T.Debt 3.95b))
RoIC = 13.11% (NOPAT 1.51b / Invested Capital 11.52b)
WACC = 6.28% (E(14.80b)/V(19.91b) * Re(8.25%) + D(5.11b)/V(19.91b) * Rd(0.75%) * (1-Tc(0.24)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.63%
[DCF] Terminal Value 87.08% ; FCFF base≈952.5m ; Y1≈1.17b ; Y5≈2.00b
[DCF] Fair Price = 843.6 (EV 51.59b - Net Debt 5.00b = Equity 46.59b / Shares 55.2m; r=6.28% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 11.74 | EPS CAGR: -42.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.55 | Revenue CAGR: 8.81% | SUE: 3.02 | # QB: 2
EPS next Quarter (2026-03-31): EPS=5.29 | Chg7d=+0.000 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=10
EPS next Year (2026-12-31): EPS=23.39 | Chg7d=+0.000 | Chg30d=-0.072 | Revisions Net=-3 | Growth EPS=+7.4% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -0.8% (Discount Rate 8.2% - Earnings Yield 9.0%)
[Growth] Growth Spread = +6.5% (Analyst 5.7% - Implied -0.8%)